Patient
Programs
Information For Patients And Families
We aim to address the needs of patients living with cancer with our relentless commitment to safer and more effective treatments.
Cancer Indications Our Programs Support
Non-Small Cell Lung Cancer (NSCLC)
What is NSCLC?
NSCLC is a disease in which malignant (cancer) cells form in the tissues of the lung. Treatment options include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Factors that affect prognosis include the stage of the cancer, type of lung cancer, and whether the cancer has mutations. Some drugs work better when there is a mutation.1
Prevalence
NSCLC is the most common type of lung cancer in the US, accounting for 82% of all lung cancer diagnoses.2
Our NSCLC Study
We are currently recruiting patients for a study of a potential NSCLC treatment.
Learn More About Our NSCLC Study
See More About Our Clinical Program in NSCLC
View Additional Educational Resources On NSCLC
National Cancer Institute
American Lung Association
Acute Myeloid Leukemia (AML)
What Is AML?
AML is a cancer of the blood and bone marrow. It is the most common type of acute leukemia in adults. This type of cancer usually gets worse quickly if it is not treated. AML is also called acute myelogenous leukemia and acute nonlymphocytic leukemia.3
Prevalence
AML is uncommon, making up about 1% of cancers and up to 31% of all adult leukemia cases. AML occurs in people of all ages, but is most common in adults older than 65.4
Our AML Study
We are currently recruiting patients for a study of a potential treatment for patients with relapsed/refractory AML.
Learn More About Our AML Study
See More About Our Clinical Program in AML
View Additional Educational Resources On AML
National Cancer Institute
Leukemia & Lymphoma Society
Myelodysplastic Syndrome (MDS)
What is MDS?
Myelodysplastic syndromes (MDS) are a group of blood and bone marrow cancers. Healthy immature blood cells in the bone marrow generally mature into red and white blood cells and platelets. In MDS, however, these bone marrow cells fail to mature, impairing the blood’s ability to carry oxygen, fight infection or clot effectively to control bleeding. In some patients, MDS can progress into AML.5
Prevalence
Around 10,000 people in the United States are diagnosed with MDS each year, with most of them being aged 70 or older. MDS is rare in people under 50.6
Our MDS Study
We are currently recruiting patients for a study of a potential treatment for patients with MDS.
Myelodysplastic syndromes (MDS) are a group of blood and bone marrow cancers. Healthy immature blood cells in the bone marrow generally mature into red and white blood cells and platelets. In MDS, however, these bone marrow cells fail to mature, impairing the blood’s ability to carry oxygen, fight infection or clot effectively to control bleeding. In some patients, MDS can progress into AML.5
Prevalence
Around 10,000 people in the United States are diagnosed with MDS each year, with most of them being aged 70 or older. MDS is rare in people under 50.6
Our MDS Study
We are currently recruiting patients for a study of a potential treatment for patients with MDS.
View Additional Educational Resources on MDS
Our Pan-Tumor Approach to Treating Solid Tumors
We are currently recruiting patients for a study of an investigational treatment for patients with advanced solid tumors, using a pan-tumor approach to determine if this molecule has activity in different types of cancer.
References
1.
National Institutes of Health. Accessed September 26, 2022. https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq.
2.
American Society of Clinical Oncology Publications. Accessed September 26, 2022. https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics.
3.
National Cancer Institute. Accessed January 12, 2023. https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq.
4.
Cancert.Net. Accessed January 12, 2023. https://www.cancer.net/cancer-types/leukemia-acute-myeloid-aml/statistics.
5.
National Cancer Institute. Accessed January 12, 2023. https://www.cancer.gov/types/myeloproliferative/patient/myelodysplastic-treatment-pdq#:~:text=Myelodysplastic%20syndromes%20are%20a%20group,blood%20cells%20and%20bone%20marrow.
6.
Tricot GJ, Lauer RC, Appelbaum FR, et al.: Management of the myelodysplastic syndromes. Semin Oncol 14 (4): 444-53, 1987.[PUBMED Abstract]
Hear From Paul, a Patient, on Finding a Cullinan Oncology Clinical Trial
Why patients and clinical trials matter
Cancer is a complex and challenging disease, and we are grateful to every patient who participates in a clinical trial to help advance our collective understanding of cancer and how new medicines work. At Cullinan Oncology, we are committed to creating safer, more effective treatments for patients living with cancer, and without patients participating in clinical trials, we wouldn’t be able to meet that commitment.
Cancer is a complex and challenging disease, and we are grateful to every patient who participates in a clinical trial to help advance our collective understanding of cancer and how new medicines work. At Cullinan Oncology, we are committed to creating safer, more effective treatments for patients living with cancer, and without patients participating in clinical trials, we wouldn’t be able to meet that commitment.
Harnessing Science for Patient Benefit
Our clinical trials are designed with clinically relevant endpoints and predefined benchmarks for success.